HEV cases were matched by year and transplant type to negative co

HEV cases were matched by year and transplant type to negative controls in a 1:3 ratio, and assessed by Chi square and multivariable conditional logistic regression. Results: Of 311 subjects (271 kidney,

33 lung, 5 heart, 2 liver) in our cohort, 16 (13 kidney, 2 lung, 1 liver) demonstrated evidence of post-transplant HEV infection (4 by HEV PCR, 2 by anti-HEV IgM,10 by anti-HEV IgG seroconversion) and were matched to 48 controls. Univariate analysis revealed significant associations between post transplant HEV infections, cyclosporine use (p=0.015), and leukopenia (p=0.007). In the multivariable model, leukopenia (OR 4.15), thrombocytopenia (OR 2.24) and tacrolimus use (OR 1.09) were associated with increased risk of HEV infection post SOT, though only leukopenia was statistically significant (p=.04). No subjects developed chronic HEV infection. Conclusions: Leukopenia was associated Adriamycin concentration with an increased risk of post-transplant HEV infection in our cohort. Associations with other variables suggest a relationship between

immunosuppression and risk of infection, but were not statistically significant. In contrast to previous studies, we did not identify any chronic HEV infections. Our findings suggest that while important, immunosuppression and exposure alone may be insufficient for the establishment of chronic HEV infection among SOT recipients. Disclosures: Kathleen B. Schwarz – Consulting: Novartis, Novartis; Grant/Research Support: Bristol-Myers Squibb, Gilead, Roche/Genentech, Bristol-Myers Squibb, Vertex, Roche The following people have nothing X-396 上海皓元 to disclose: Paul K. Sue, Nora Pisanic, Christopher D. Heaney, Kenrad Nelson, Alexandra Valsamakis, Michael Forman, Annette M. Jackson, John R. Ticehurst, Robert A. Montgomery, Wikrom Karnsakul Histological recurrence of hepatitis C (HCV) post-liver transplantation (LT) is still an important event even in the era of more effective HCV treatments. The Hepatitis Aggressiveness Score (HAS) is a histologic classification system that has been

recently developed to assess the recurrence of HCV. Objective: the main outcome of the study was to evaluate graft survival time based on HAS and to assess pathologist inter-observer agreement. Methods: we reviewed the clinical records of HCV liver transplant recipients in our facility from June 1999 to June 2012. We included those patients who had >30 day survival. Clinical and histologic characteristics were obtained. Biopsies were independently evaluated by 3 pathologists. All biopsies were assessed for the presence of the following features, which comprise the basis of the HAS: 1) prominent ductular reaction 2) prominent hepatocyte ballooning 3) cholestasis (including at least focal canalicular cholestasis of any degree) and 4) periportal sinusoidal/pericellular fibrosis.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>